NCT05941507: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 300 planned
- Started
- 5 Oct 2023
- Primary completion
- Jan 2027
- Arms
- LCB84 + anti-PD-1
- Results
- None posted
- 12 Jul 2023: Trial registered
- 5 Oct 2023: Trial started